Evotec shares lose a third of their value on cloudy outlook
By Steve Goldstein
Shares of German biotech Evotec lost a third of their value on Wednesday on an uncertain outlook as it named a new chief executive.
The Hamburg, Germany-based company reported 2023 financials near consensus estimates, as its adjusted earnings before interest, tax, depreciation and amortization fell 35% to EUR66 million as revenue rose 4% to EUR781 million. Analysts polled by FactSet expected EBITDA of EUR61 million on sales of EUR782 million.
Evotec (XE:EVT) - upgraded to buy from hold at Deutsche Bank two weeks ago - also named a permanent CEO, turning to Christian Wojczewski, the chief executive of Dutch medical devices company Mediq, who will replace interim CEO Mario Polywka in July.
The company forecast double-digit growth in both adjusted EBITDA and revenue for 2024 and said "refined guidance" will be assessed by the new CEO, with the company giving a mid-term outlook at its first-half results, due in August.
Analysts had expected EBITDA to more than double, to EUR159.5 million, according to FactSet.
It said a "priority reset" that will involve simplifying its organizational structure and operating model while optimizing footprint and capacity will lift earnings by at least EUR40 million per year.
Evotec shares skidded by 34%, by far the worst performance in the Stoxx Europe 600.
Evotec's leading shareholders include Novo Nordisk Foundation investor Novo Holdings and Mubadala Investment Co., one of Abu Dhabi's sovereign wealth funds.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-24-24 0358ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software